Published in PLoS One on April 09, 2012
Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol (2013) 1.10
Hydrogen sulfide signaling in the gastrointestinal tract. Antioxid Redox Signal (2013) 0.97
Endogenous prostaglandins and afferent sensory nerves in gastroprotective effect of hydrogen sulfide against stress-induced gastric lesions. PLoS One (2015) 0.92
Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific, pro-resolution mechanism. PLoS One (2013) 0.88
The H2S-releasing naproxen derivative, ATB-346, inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis. Med Gas Res (2015) 0.87
Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention. J Invest Dermatol (2014) 0.86
Hydrogen sulfide: physiological properties and therapeutic potential in ischaemia. Br J Pharmacol (2015) 0.86
Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges. Gastroenterol Res Pract (2013) 0.81
Functional and molecular insights of hydrogen sulfide signaling and protein sulfhydration. J Mol Biol (2016) 0.80
Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice. J Neuroinflammation (2014) 0.79
Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol (2014) 0.78
NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol (2015) 0.78
Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling. Drug Des Devel Ther (2015) 0.77
Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. PLoS One (2014) 0.77
Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction. Inflammopharmacology (2015) 0.76
Toward More GI-Friendly Anti-Inflammatory Medications. Curr Treat Options Gastroenterol (2015) 0.76
Indomethacin injury to the rat small intestine is dependent upon biliary secretion and is associated with overgrowth of enterococci. Physiol Rep (2016) 0.75
Profound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal Tumorigenesis. PLoS One (2016) 0.75
Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury. Dig Dis Sci (2017) 0.75
International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol Rev (2017) 0.75
Antiulcerogenic activity of Carica papaya seed in rats. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology (1993) 4.93
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology (2011) 3.29
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol (2005) 2.54
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol (2005) 2.50
Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology (1998) 2.46
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology (2000) 2.43
Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol (1990) 2.36
A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology (1995) 2.30
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol (2006) 2.21
A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology (2005) 2.17
Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol (1969) 2.13
Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology (2000) 1.97
Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology (1972) 1.88
Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev (2008) 1.82
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology (2004) 1.79
Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol (2008) 1.71
Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology (1997) 1.69
Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol (2006) 1.64
Hydrogen sulfide enhances ulcer healing in rats. FASEB J (2007) 1.61
Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol (2002) 1.61
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology (2006) 1.59
Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci (2007) 1.59
Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. J Proteome Res (2009) 1.57
Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. Am J Med Sci (2011) 1.41
Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol (2010) 1.34
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther (1997) 1.26
Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol (2003) 1.22
NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol (2000) 1.14
The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol (2003) 1.11
Gastric ulceration: critical events at the neutrophil--endothelium interface. Can J Physiol Pharmacol (1993) 1.08
NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol (2012) 1.03
Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol (1998) 1.03
Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol (1996) 1.02
Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest (2010) 0.99
Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology (1995) 0.99
Microcirculatory disturbance in indomethacin-induced intestinal ulcer. Am J Physiol (1991) 0.93
Morphology of pancreatic islets: a time course of pre-diabetes in Zucker fatty rats. Methods Mol Biol (2009) 0.88
Toxicity of nonsteroidal anti-inflammatory drugs in the elderly: is advanced age a risk factor? Am J Med (1997) 0.88
Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs. Dig Liver Dis (2000) 0.84
Exacerbatory mechanism responsible for water immersion stress-induced gastric lesions in aged rats compared with young rats. Clin Exp Pharmacol Physiol (2001) 0.82
Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers. Am J Physiol Gastrointest Liver Physiol (2000) 0.81
Thromboxane synthesis and blood pressure in spontaneously hypertensive rats. Hypertension (1986) 0.77
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 3.58
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology (2011) 3.29
Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell (2008) 2.65
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci (2004) 2.64
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
An Aging Interventions Testing Program: study design and interim report. Aging Cell (2007) 2.54
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology (2006) 2.08
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A (2004) 1.76
Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A (2006) 1.69
Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem (2010) 1.63
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc Res (2012) 1.45
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A (2005) 1.45
Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. Cardiovasc Drugs Ther (2013) 1.40
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci U S A (2003) 1.32
Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem (2004) 1.23
Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can J Physiol Pharmacol (2003) 1.17
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A (2002) 1.13
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A (2003) 1.11
Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev (2005) 1.11
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09
Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. Dig Liver Dis (2009) 1.06
Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med (Maywood) (2006) 1.06
Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol (2008) 1.03
Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. J Neurochem (2005) 1.02
Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett (2006) 1.02
A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A (2010) 1.01
Retracted A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol (2002) 1.01
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther (2006) 1.00
Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. J Pharmacol Exp Ther (2002) 0.99
Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid. J Med Chem (2008) 0.99
Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow. Br J Pharmacol (2005) 0.98
Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J Neurochem (2004) 0.98
Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One (2012) 0.98
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci (2002) 0.97
Hydrogen sulfide: a rescue molecule for mucosal defence and repair. Dig Dis Sci (2012) 0.97
Letter by Wallace and Chan regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin". Circulation (2013) 0.96
Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res (2011) 0.95
Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann N Y Acad Sci (2002) 0.95
Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. Am J Physiol Gastrointest Liver Physiol (2011) 0.95
Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol (2003) 0.94
Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. Apoptosis (2006) 0.94
Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. J Neurochem (2004) 0.94
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can J Gastroenterol (2004) 0.94
Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) (2005) 0.94
Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Natl Acad Sci U S A (2002) 0.93
Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol Sci (2009) 0.93
Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. J Pharmacol Exp Ther (2004) 0.93
Nitric oxide and inflammation. Inflamm Allergy Drug Targets (2006) 0.93
Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol (2002) 0.92
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology (2003) 0.92
Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. Am J Physiol Gastrointest Liver Physiol (2013) 0.92
A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther (2010) 0.91
Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br J Pharmacol (2002) 0.91
Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation (2004) 0.91
A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner. Am J Physiol Gastrointest Liver Physiol (2008) 0.90
Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am J Physiol Heart Circ Physiol (2002) 0.90
Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. J Transl Med (2007) 0.89
Up-regulation of ORL-1 receptors in spinal tissue of allodynic rats after sciatic nerve injury. Eur J Pharmacol (2002) 0.89
Hydrogen sulfide and resolution of acute inflammation: A comparative study utilizing a novel fluorescent probe. Sci Rep (2012) 0.89
Interactions of hydrogen sulfide with myeloperoxidase. Br J Pharmacol (2014) 0.89
Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. PLoS One (2012) 0.89
Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol (2003) 0.88
Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific, pro-resolution mechanism. PLoS One (2013) 0.88
Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am J Pathol (2005) 0.87
A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. FASEB J (2013) 0.87
A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 0.87
NO-donating aspirin and aspirin partially inhibit age-related atherosclerosis but not radiation-induced atherosclerosis in ApoE null mice. PLoS One (2010) 0.85
Roles of platelets and proteinase-activated receptors in gastric ulcer healing. Dig Dis Sci (2005) 0.85
Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages. Eur J Pharmacol (2006) 0.85
Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]. J Pharmacol Exp Ther (2004) 0.85
Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol Cancer Ther (2006) 0.84
A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury. Br J Pharmacol (2003) 0.84
Hydrogen sulfide inhibits oxidative stress in lungs from allergic mice in vivo. Eur J Pharmacol (2012) 0.84
Dynamic regulation of microglial functions by the non-steroidal anti-inflammatory drug NCX 2216: implications for chronic treatments of neurodegenerative diseases. Neurobiol Dis (2005) 0.84
Nitric oxide synthase and nitric oxide production in in vivo-derived mast cells. J Leukoc Biol (2002) 0.83
Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm Bowel Dis (2015) 0.83
Citrobacter rodentium infection causes iNOS-independent intestinal epithelial dysfunction in mice. Can J Physiol Pharmacol (2006) 0.83
Environmental and NSAID-enteropathy: dysbiosis as a common factor. Curr Gastroenterol Rep (2014) 0.82
A protease activated receptor-2 (PAR-2) activating peptide, tc-LIGRLO-NH2, induces protease release from mast cells: role in TNF degradation. BMC Pharmacol (2004) 0.82
Mucosal repair and COX-2 inhibition. Curr Pharm Des (2003) 0.82
Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin. Eur J Med Chem (2003) 0.82
In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J Transl Med (2005) 0.81
Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. Am J Physiol Gastrointest Liver Physiol (2015) 0.81
Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate (2004) 0.81
Glutamate efflux from human cerebrocortical slices during ischemia: vesicular-like mode of glutamate release and sensitivity to A(2A) adenosine receptor blockade. Neuropharmacology (2004) 0.81
The distinct alterations produced in cardiovascular functions by prednisolone and nitro-prednisolone (NCX-1015) in the rat highlight a causal role for endothelin-1. J Pharmacol Exp Ther (2004) 0.81
Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice. Muscle Nerve (2012) 0.80
Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology (2003) 0.80